Perosphere Gains Irish Distribution Partner for its POC Coagulator

Perosphere Technologies Inc. has signed an agreement with M3 Medical to exclusively distribute its Point-of-Care (PoC) Coagulometer in Ireland.
 
The Emerald Isle will be the first country in which Perosphere’s PoC Coagulometer will become available to hospitals and health facilities. “We are excited to partner with M3 Medical based on the company’s expertise and demonstrated success in the medical device market to improve patient care,” Perosphere Chief Operating Officer Daryl Mootoo said. “We trust in M3 Medical’s capabilities to bring Perosphere’s PoC Coagulometer to healthcare providers in Ireland and help us change the current standard of testing and care in anticoagulation management.”
 
Many patients require anticoagulants, which help prevent blood clots and stroke. Perosphere’s PoC Coagulometer is the only pharmacodynamic, reagent-free diagnostic tool for use at the point-of-care—i.e., bedside. The PoC Coagulometer test results can assist doctors and other health care professionals (HCPs) in the rapid diagnosis of coagulation status and enabling informed treatment decision-making in emergency and other medical settings. The PoC Coagulometer provides HCPs with diagnostic results in three to eight minutes.
 
Perosphere’s PoC Coagulometer has a CE Mark in the European Union. 
 
“When searching for a distributor for Ireland, in addition to operational excellence, we also wanted a partner with a well-established team,” Perosphere Vice President of Europe Sales David Walker noted. “M3 Medical has deep relationships with clinicians, hospitals, and clinic decision-makers, making them an ideal partner.”
 
M3 Medical is a medical device distributor for interventional cardiology, radiology, neuroradiology, vascular surgery, and cardiac rhythm management in Ireland and the United Kingdom. M3 Medical operates under Uniphar Medtech, a European medical device distributor headquartered in Ireland with a presence across 21 markets.
 
“We recognize the value of Perosphere’s unique coagulation testing device, especially in Ireland given the widespread use of anticoagulants and the unmet need for fast and complete coagulation diagnosis,” added Robbie Dolan, Business Unit Leader – Ireland of M3 Medical. “We are proud to enter into this exclusive agreement in order to help improve patient outcomes and reduce health system costs in Ireland.”
 
Perosphere Technologies is a private medical technologies company developing and commercializing the PoC (point-of-care) Coagulometer, which quickly informs diagnosis, treatment, and prevention decisions through precision data, made immediately accessible to all. It is the only PoC diagnostic tool that effectively and swiftly tests clotting times across drug classes, including the Direct Oral Anticoagulants (DOACs), according to the company. The PoC Coagulometer serves to help establish a new standard of care for patients on anticoagulant therapies or at risk for bleeding, and has the potential to improve efficiency, provide significant cost savings, and support better patient outcomes. The PoC Coagulometer is not U.S. Food and Drug Administration cleared in the United States.

M3 Medical distributes medical devices, specializing in interventional cardiology, radiology, neuroradiology, vascular surgery, and cardiac rhythm management. Its expertise lies in identifying and introducing innovative technologies to healthcare professionals across Ireland and the United Kingdom. As part of Uniphar Medtech, a European medical device distributor with a presence in 21 markets, M3 Medical leverages an extensive support network.